CVC Capital Partners wants to pay roughly $12 billion to take Recordati, one of Italy's most storied pharmaceutical companies, off the public market entirely. Six board members called the offer fair this week. Four did not. That split tells you something important about who wins and who loses when a private equity firm buys a publicly traded drugmaker and closes the door behind it.

The offer, made jointly by CVC and Belgian investment group Groupe Bruxelles Lambert, prices each Recordati share at €51.29 (about $58.80). When the board voted Wednesday, the stock was trading at almost exactly that price. On paper, shareholders are getting fair value. In practice, the four independent directors who dissented argued that the offer fails to capture what Recordati is actually worth going forward, including its growing rare-disease business, which tends to command the highest valuations in pharmaceuticals.

Why this deal is happening now

CVC is not arriving as a stranger. The firm has controlled a vehicle holding a 46.8% stake in Recordati since 2018, giving it effective dominance over the company for years. A non-binding expression of interest in March was really just CVC announcing its intention to consolidate what it already partially owned and remove the inconvenience of public shareholders asking hard questions at earnings calls.

The timing fits a broader pattern in Italian pharma. Recordati's sector has seen a wave of consolidation in recent years, and with European interest rates now lower than their 2023 peaks, financing large buyouts has become meaningfully cheaper. CVC's calculation is that Recordati is worth more as a private company with room to make bold acquisitions, free from the quarterly scrutiny that public markets impose.

The board's majority agreed with that logic. Their statement pointed to the "greater flexibility" of operating as a privately held company and the ability to pursue long-term strategic initiatives without public market pressure.

What delisting actually means

When a company like Recordati goes private, three things typically follow.

First, ordinary investors lose access. If you held Recordati shares through a European pension fund or an index, you will be cashed out at the offer price and that is the end of your participation in whatever growth the company achieves over the next decade.

Second, disclosure shrinks. Public companies must publish detailed financials, explain pricing decisions, and account for major changes in strategy. Private companies do not. For a pharmaceutical firm that operates in rare diseases, where a single drug can cost patients tens of thousands of euros per year, that reduced transparency is not a trivial concern.

Third, the strategy shifts toward an eventual exit. Private equity firms buy companies to sell them again, typically within five to eight years. Every decision in between, including pricing, research spending, and acquisitions, is made with that exit in mind. That is not inherently bad, but it is a different set of incentives than a publicly held company faces.

The dissent worth watching

The four independent directors who voted against the deal acknowledged the strategic rationale. They were not saying the deal was irrational or that CVC was acting in bad faith. They were saying €51.29 per share is not enough, specifically because it does not reflect Recordati's future prospects adequately.

That is a meaningful objection in a deal where CVC already controls nearly half the company. When the majority shareholder makes a buyout offer, minority shareholders have limited leverage. The independent directors dissenting is essentially the only institutional check available to them, and it failed to stop the deal.

Recordati was founded a century ago as a family pharmacy in central Italy. It now covers primary care, consumer health, and rare diseases across dozens of countries. Whether CVC's ownership will accelerate that trajectory or redirect it toward a profitable exit is the question public shareholders will no longer be around to answer.